ESR1 and breast cancer: Most mechanistic studies have been carried out in breast cancer cell lines, which are clonally selected, and since breast tumors are heterogeneous, we utilized two PDX tumor models to elucidate the role of transcriptionally functional ER in the CDK4/6 inhibitor response.